Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsForexCryptocurrenciesCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Drugmakers slash prices to be eligible for China's bulk-buy program

share with twitter share with LinkedIn share with facebook
share via e-mail
01/18/2020 | 03:21am EST
FILE PHOTO: Illustration photo shows various medicine pills in their original packaging in Brussels

Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday.

Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement.

Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.

In the latest bidding on Friday that involved 33 drugs and 122 companies, Bayer slashed the price of its popular diabetes treatment Acarbose to 0.18 yuan ($0.0262) per pill, 78.5% lower than the price ceiling set by the government in December last year, elbowing some Chinese generic providers out of the tender, according to a Reuters calculation based on the preliminary results released by the authority overseeing the program.

Bayer was not immediately available for a comment.

"Products that won bids in this round of centralized procurement saw a huge price drop, which squeezes out unreasonable overpricing that has existed in drug distribution for a long time," the authority said in a statement published alongside the preliminary result on Friday.

Sale prices of over 100 types of commonly used drugs are on average about 17 to 18 times of their manufacturing costs, the statement said.

Chinese copycats won bids for most of the 33 drugs, including generic versions for drugs ranging from Johnson & Johnson's prostate cancer treatment Zytiga to Eli Lilly's erectile dysfunction treatment Cialis, the results showed.

In Friday's bidding, for products with two bid winners, 60% of the government procurement volume can be shared among the winners, according to official document detailing the tender rules released in December. For products with four winners and more, as much as 80% of the volume can be shared among the companies.

In the first round of the nationwide implementation of the bulk-buy program in September, global drugmakers including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.

(Reporting by Roxanne Liu and Brenda Goh; Editing by Muralikumar Anantharaman)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -3.17% 7446 Delayed Quote.1.09%
BAYER AG -4.85% 70.5 Delayed Quote.1.76%
MERCK AND COMPANY -1.23% 81.33 Delayed Quote.-9.47%
MERCK KGAA -4.88% 118 Delayed Quote.17.75%
PROCTER & GAMBLE COMPANY -2.68% 123.3 Delayed Quote.1.44%
SANOFI -1.89% 91.57 Real-time Quote.4.14%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.08% 7.03469 Delayed Quote.1.34%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news "Companies"
07:09pSEEK : FY20 Half Year Results Announcement
07:09pSEEK : FY20 Half Year Results Presentation
07:08pCOOPER-STANDARD : 4Q Earnings Snapshot
07:07pApergy Reports Full Year and Fourth Quarter 2019 Results
07:04pJAPAN EXCHANGE : Shionogi's FETROJA(R) (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.
07:04pVINDA INTERNATIONAL : Next Day Disclosure Returns
07:04pResponse to SGX Queries
07:04pGENERAL ANNOUNCEMENT : :Teleconference - Half Year Results to 31 December 2019
07:04pREQUEST FOR LIFTING OF TRADING HALT : :Request for Lifting of Trading Halt
07:03pBoeing Nominates Two New Directors for Board -- Update
Latest news "Companies"